11th Annual MassBio Investors Forum
Tuesday, October 6 2009
11th Annual MassBio Investors Forum
Tue, October 6
Noubar Afeyan, PhD, Managing Partner and CEO, Flagship Ventures
Katrine Bosley, CEO, Avila Therapeutics
Steven Burrill, CEO, Burrill & Company
Timothy Coetzee, Ph.D., President, Fast Forward, LLC
Alan Crane, General Partner, Polaris Venture Partners
Robert Coughlin, President & CEO, Massachusetts Biotechnology Council
Barbara Dalton, Vice President, Venture Capital, Pfizer, Inc.
Louis J. DeGennaro, Ph.D., Chief Scientific Officer, The Leukemia & Lymphoma Society (LLS)
Barry Greene, President and Chief Operating Officer, Alnylam Pharmaceuticals, Inc.
Mike Diem, Partner, SR One
Richard A. Insel, M.D., Executive Vice President, Research, Juvenile Diabetes Research Foundation
Vaughn M. Kailian, Managing Director, MPM Capital, LLC
Scott Jackson, R.Ph., M.B.A., Chief Executive Officer, Celator Pharmaceuticals
Maggie Flanagan LeFlore, Ph.D., Managing Director, MedImmune Ventures
Reid J. Leonard, Ph.D., Executive Director, Licensing And External Research, Merck & Co., Inc.
Mark Leuchtenberger, Chairman, Massachusetts Biotechnology Council
James J. O'Mara, Vice President, Business Development, Ironwood Pharmaceuticals, Inc.
Cat Oyler, Sr. Director, Emerging Technologies, Office of Science and Technology, Johnson & Johnson
Gary Pisano, Harry E. Figgie, Jr. Professor of Business Administration, Harvard Business School, and author of Science Business: The Promise, The Reality and The Future of Biotech
Douglas J. Ringler, VMD, Cofounder, President & Chief Executive Officer, Tolerx
Bharat Tewarie, MD, MBA, Vice President, Head of Business Development USA , Head of Global Business Development Endocrinology/Fertility, EMD Serono Inc.
Ted Torphy, CSO & Head, External Research, Johnson & Johnson
Ed Torres, Managing Director, Lilly Ventures
Michael Weingarten, Director, NCI Small Business Innovation Research Development Center, National Cancer Institute
Lawrence Wittenberg, Partner, Goodwin Procter, LLP
Noubar Afeyan, PhD
Managing Partner and CEO
Noubar Afeyan is Managing Partner and CEO of Flagship Ventures, a firm he co-founded in 2000. He is also a Senior Lecturer at MIT in both the Sloan School of Management and the Biological Engineering Department. Dr. Afeyan has authored numerous scientific publications and patents since earning his Ph.D. in Biochemical Engineering from MIT in 1987.
A technologist, entrepreneur and venture capitalist, Dr. Afeyan has co-founded and helped build over 20 successful life science and technology startups during the past two decades. He was founder and CEO of PerSeptive Biosystems (Nasdaq: PBIO), a leader in the bio-instrumentation field. After PerSeptive's acquisition by Applera Corporation (NYSE: ABI), he was Senior Vice President and Chief Business Officer of Applera, where he initiated and oversaw the creation of Celera Genomics (Nasdaq: CRA).
Currently Dr. Afeyan serves on a number of public and private company boards. He is a director and co-founder of Flagship portfolio companies Affinnova, BG Medicine, Ensemble Discovery, Genstruct, Helicos BioSciences (NASDAQ:HLCS), Joule Biotechnologies and LS9. Previously he was a member of the founding team, director and investor in several successful ventures including Chemgenics Pharmaceuticals, Color Kinetics, Antigenics, EXACT Sciences and Adnexus Therapeutics.
Dr. Afeyan is a member of the Board of Overseers of Boston University, the Board of Visitors of Boston University School of Medicine, and the Board of Overseers of the Boston Symphony Orchestra. In addition, he is a member of several advisory boards including the Whitehead Institute at MIT, the Harvard-MIT Division of Health Sciences and Technology (HST) and the SKOLKOVO School of Management in Moscow. Dr. Afeyan is also co-founder and board member of Armenia 2020 and the National Competitiveness Foundation of Armenia, two international economic development projects focusing on the former Soviet Republic of Armenia. In 2008 he received an Ellis Island Medal of Honor, an award granted to outstanding Americans who have distinguished themselves as U.S. citizens and who have enabled their ancestry groups to maintain their identities while becoming integral parts of American life.
Chief Executive Officer
Ms. Bosley is a biotechnology executive with two decades of industry leadership experience across a spectrum of key corporate and strategic functions. Prior to joining Avila, Ms. Bosley served as Vice President, Business Development and later as VP, Strategic Operations at Adnexus, establishing an alliance with and subsequent acquisition by Bristol-Myers Squibb. During her career she has worked with products from discovery through commercialization, including Avonex®, Tysabri® and the emerging Adnectin™ class of targeted biologics. Ms. Bosley was with Biogen Idec for many years where she held leadership roles in business development, commercial operations and portfolio strategy in both the U.S. and Europe. She also held positions at Highland Capital Partners, a venture capital firm, and Alkermes, a leading biotechnology company. Ms. Bosley is a graduate of Cornell University.
G. Steven Burrill
Chief Executive Officer
Burrill & Company
G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. An early pioneer, Mr. Burrill is one of the original architects of the industry and one of its most avid and sustained developers. He currently serves as Chairman of the Boards of Pharmasset (NASDAQ: VRUS), BioImagene and NewBridge, and is a member of the Boards of Directors of Catalyst Biosciences, CrossCart, DepoMed (NASDAQ: DEPO), Ikano Therapeutics, Phytomedics, Proteogenix, Proventys, Targacept (NASDAQ: TRGT) and XDx. Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide. In 2002, Mr. Burrill was recognized as the biotech investment visionary by the prestigious Scientific American magazine (The Scientific American 50), and in 2008, he received the BayBio Pantheon 2008 DiNA lifetime achievement award for his worldwide biotech leadership.
In addition to his work with leading life science companies, Mr. Burrill is a founder and currently serves as the Chairman of the Board of the Foundation for the National Medals of Science and Technology. Additionally, he serves as Chairman of the San Francisco Mayor’s Biotech Advisory Committee (MAYBAC). Other not-for-profit activities include serving on the Boards of Directors of the Bay Area Science Infrastructure Consortium, BayBio, California Healthcare Institute (Emeritus), The Exploratorium, The Kellogg Center for Biotechnology, the University of Maryland Biotechnology Institute, the MIT Center for Biomedical Innovation, Kramden Institute, and the National Health Museum. He also serves on the Purdue Discovery Park External Advisory Committee as well as the editorial board of the Journal of Commercial Biotechnology, is on the advisory board of the Center for Policy on Emerging Technologies (C-PET) and serves as an advisor to University of Illinois Institute for Genomic Biology, University of Wisconsin—College of Agriculture and Life Sciences, Carnegie Mellon, and Duke University, and is an adjunct professor at University of California, San Francisco.
Timothy Coetzee, Ph.D.
Fast Forward, LLC
Timothy Coetzee, Ph.D., is the President of Fast Forward, LLC, a venture philanthropy of the National Multiple Sclerosis Society. He is responsible for the Society’s strategic funding of biotechnology and pharmaceutical companies as well as partnerships with the financial and business communities. Prior to assuming his current position, Dr. Coetzee led the Society’s translational research initiatives on nervous system repair and protection in multiple sclerosis (MS) as well as the Society’s programs to recruit and train physicians and scientists in MS research. Dr. Coetzee received his Ph.D. in Molecular Biology from Albany Medical College in 1993 and has since been involved in MS research. He was a research fellow in the laboratory of Society grantee Dr. Brian Popko at the University of North Carolina–Chapel Hill, where he received an Advanced Postdoctoral Fellowship Award from the Society. After completing his training with Dr. Popko, Dr. Coetzee joined the faculty of the Department of Neuroscience at the University of Connecticut School of Medicine, where he conducted research that applied new technologies to understand how myelin is formed in the nervous system. He is the author of a number of research publications on the structure and function of myelin. Dr. Coetzee joined the National MS Society’s Home Office staff in fall 2000.
Polaris Venture Partners
Alan Crane is a general partner in our Boston office, he joined Polaris in 2002 as a venture partner and focuses his investments in life sciences.
From 2006 to 2009, Alan co-founded and served as CEO of Cerulean Pharma (a nanotechnology focused pharmaceutical company) and co-founded Parasol Therapeutics (an influenza company). From 2002 until 2006, Alan was President and CEO of Momenta Pharmaceuticals. He joined Momenta as the fifth employee and built the company into a public company, creating an advanced and diversified pipeline, entering into two strategic collaborations with the Sandoz division of Novartis, and raising $275 million. Prior to this, he was senior vice president of global corporate development at Millennium Pharmaceuticals, where he was responsible for leading Millennium's strategic partnering, mergers and acquisitions, and licensing activities, generating over $2 billion in partner funding and acquiring 19 development stage products. Prior to Millennium, Alan was a marketing executive at Dupont-Merck and a consultant with the Boston Consulting Group and Arthur D. Little.
He serves on the boards of Momenta Pharmaceuticals, T2 Biosystems, Hydra Biosciences, Seventh Sense Biosystems, Vaccinex and is also a founder and chairman of the board of Ceruelan Pharma Inc and Parasol Therapeutics. Previously, he served on the boards of Sirtris Pharmaceuticals (acquired by Glaxo SmithKline) and Adnexus (acquired by Bristol Myers Squibb). He serves on several non-profit boards including the trust board of Children's Hospital Boston, the Autism Consortium, and Medicine in Need.
He received his M.B.A. in 1992 and his B.A. summa cum laude and M.A. in 1986, all from Harvard University. Alan also attended Harvard Medical School from 1986 to 1988 before pursuing a business career.
Barbara J. Dalton, Ph.D.
Vice President, Venture Capital
Barbara is a pharmaceutical executive who has spent over 25years in the industry - most of that time as a corporate venture capitalist. At Pfizer she is responsible for growing their corporate venture activities, managing the current equity portfolio and advising on structured equity transactions. She was trained as a research scientist in a virology and immunology laboratory at The Medical College of Pennsylvania where she received her Ph.D. She pursued inflammation drug discovery research at SmithKline’s research laboratories and joined their venture capital group, S.R. One, Limited in the early 1990’s. While there Barbara was a founding member of EuclidSR Partners, a private New York based venture capital firm where SmithKline (now GSK) was a leading limited partner. She joined that firm full time in 2003. In 2007 she moved to her current position at Pfizer. Barbara has managed over 20 fund investments and 60 diverse company investments in the US and Europe and has had direct investing responsibility for biotechnology therapeutic and platform technology companies, as well as some healthcare IT and service businesses. She has routinely represented her firms investments by participating at the board level in companies such as: Alere, Ciphergen, Corixa, Genset, Gliatech, Gryphon, Lexicon, OGS, Third Wave, Rib-X. In the community she has been active in her regional venture investors association, the MAC Alliance, serving as Chairman, and supported the venture philanthropy efforts of the Institute for the Study of Ageing as a board member. She is an advisor to the Dean of the Eberly College of Science, where she received her undergraduate degree, and a member of The Penn State Research Foundation Board of Directors. She is also a member of the board of the New York Biotech Association and the National Venture Capital Association.
Louis J. DeGennaro, Ph.D.
Chief Scientific Officer
The Leukemia & Lymphoma Society (LLS)
Dr. DeGennaro's responsibilities include administration of LLS's research grant programs that support research leading into the prevention, diagnosis and cure of leukemia, lymphoma and myeloma. He also directs LLS's Therapy Acceleration Program, which supports private sector and academic-based projects with the goal of moving more blood cancer therapies into the development pipeline.
Dr. DeGennaro has more than 20 years of research and drug development experience in academic and private sector settings. He received his Ph.D. in biochemistry from the University of California at San Francisco and did his post-doctoral research at Yale University School of Medicine. His previous academic positions include research group leader, Max Planck Institute in Munich, Germany, and associate professor of neurology and cell biology, University of Massachusetts Medical School. Dr. DeGennaro's private sector positions include: senior director of molecular genetics at Wyeth Pharmaceuticals, Princeton, NJ, and executive vice president for research and development, SynX Pharma, Inc. in Toronto, Canada.
Michael C. Diem
Mike joined SR One in 2005 and is a Kauffman Fellow. He is currently a board director at CalciMedica, Synovex, Trinity Biosystems and NuPathe, Inc. Other portfolio companies that he was responsible for included Protez Pharmaceuticals (acquired by NVS in 2008) and Metastatix, Inc. He has 9 years of clinical experience and completed his residency training at Duke University Medical Center. Mike has an MD from the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, and an MBA from Case Western Reserve University.
President and Chief Operating Officer
Alnylam Pharmaceuticals, Inc.
Barry Greene joined Alnylam in September 2003, bringing over 15 years of experience in healthcare industries and consulting. Prior to Alnylam, he was General Manager of Oncology at Millennium Pharmaceuticals, Inc., where he led the company's global strategy and execution for its oncology business including strategic business direction and execution, culminating in the successful approval and launch of VELCADE™ (bortezomib) in mid 2003. Prior to joining Millennium in February 2001, Mr. Greene served as Executive Vice President and Chief Business Officer for Mediconsult.com. Prior to Mediconsult.com, Mr. Greene's past experiences include Vice President of Marketing and Customer Services for AstraZeneca formerly AstraMerck; Vice President Strategic Integration with responsibility for the AstraZeneca North American post merger integration; and Partner, Andersen Consulting responsible for the pharmaceutical/biotechnology marketing and sales practice. Mr. Greene received his B.S. in Industrial Engineering from University of Pittsburgh. He also serves as Senior Scholar at Duke University, Fuqua School of Business and is a Board Member of Acorda Therapeutics, Inc., Regulus Therapeutics, LLC and the Biomedical Enterprise Program, Harvard MIT Division of Health Sciences and Technology - a joint program of Harvard Business School and MIT Sloan School.
Richard A. Insel, M.D.
Executive Vice President, Research
Juvenile Diabetes Research Foundation
Richard A. Insel, M.D., is the Executive Vice President of Research for the Juvenile Diabetes Research Foundation, where he has responsibility for heading up the strategic direction and oversight of all JDRF research projects.
Dr. Insel has had a distinguished medical and research career in pediatric immunology. Prior to joining JDRF in 2003, he held various leadership positions at the University of Rochester Medical Center during a 26-year tenure there. Dr. Insel was the founding director of the Center for Human Genetics and Molecular Pediatric Disease and a member of the departments of pediatrics and microbiology & immunology. Among other responsibilities, Dr. Insel served as Acting Chair of Pediatrics; Professor of Pediatrics, Microbiology & Immunology, and the Cancer Center; Associate Chair for Pediatric Research; Director of the Strong Children's Research Center; and Chief of the Division of Pediatric Immunology, Allergy and Rheumatology.
Dr. Insel was a scientific co-founder of Praxis Biologics, a biotechnology company established in 1983 and subsequently acquired by Wyeth, the global pharmaceutical and health care products company. Praxis Biologics was responsible for bringing a new vaccine to market that resulted in the virtual elimination of the most common form of childhood meningitis among American infants and children.
Dr. Insel has served on the National Advisory Allergy and Infectious Diseases Council of the National Institutes of Health. He has been a Visiting Associate Professor of Biochemistry and Biophysics at Columbia University's College of Physicians and Surgeons, a fellow in pediatrics (research) at Harvard Medical School, and a fellow in medicine (immunology) at Children's Hospital Medical Center in Boston. He also served in the Laboratory of Parasitic Immunochemistry at the Centers for Disease Control in Atlanta.
Scott Jackson, R.Ph., M.B.A.
Chief Executive Officer
Mr. Jackson was appointed to his current position in April 2008. He joined Celator Pharmaceuticals in October 2007 as Head of Commercial Development. Mr. Jackson has more than 20 years of experience in the pharmaceutical and biotechnology industry and has held positions of increasing responsibility in sales, marketing, and commercial development at Eli Lilly & Co., SmithKline Beecham, ImClone Systems Inc., Centocor (Johnson & Johnson), Eximias Pharmaceuticals and YM BioSciences (acquired Eximias). Mr. Jackson holds a B.S. in Pharmacy from the Philadelphia College of Pharmacy and Science and an M.B.A. from University of Notre Dame.
Vaughn M. Kailian
MPM Capital, LLC
Mr. Kailian is the Chairman of the Board of Elixir Pharmaceuticals, Inc. , Cerimon Pharmaceuticals, Inc and Valeritas, Inc.. He is also a director of Cephalon, Inc., NicOx, S.A. and Xanodyne, Inc. He is currently a member of the board of BIO (the Biotechnology Industry Organization), BIOVentures for Global Health and the New England Healthcare Institute.
He earned his B.A. degree at Tufts University.
Maggie Flanagan LeFlore, PhD
Maggie, who joined MedImmune Ventures as a managing director in 2007, transitioned into the role from her position as Head of R&D Ventures at AstraZeneca. As Head of R&D Ventures, she was on assignment to Advent International where she worked with the Healthcare and Life Sciences venture capital investment team. Previously, Maggie was the Global Alliance Director for Global Sciences and Information from 2001 to 2005, where she led an international group responsible for evaluation, negotiation and management of global technology platform collaborations. Prior to 2001, Maggie held business development and scientific management positions at Hybridon, Inc. (1997-2000); Oncogene Science Inc. (1994-1996); and Merrell Dow Pharmaceuticals (1985-1994). Originally trained as a biophysical chemist, with a B.S. in Chemistry from the University of Kansas, and a Ph.D. in Physical Chemistry from Indiana University, she trained in molecular and cellular biology as a post-doctoral fellow at the National Institutes of Health. Maggie is a board observer of Inotek, Inc, NKT Therapeutics, and Brain Cells, Inc.
Lt. Governor Timothy P. Murray
Commonwealth of Massachusetts
Throughout his public career, Tim Murray has taken on the tough challenges of economic development, improving public education, protecting the environment and making government more responsive to every citizen.
Prior to his election as Lieutenant Governor, Tim was a three-term mayor of Worcester, Massachusetts’ second largest city. Under Tim’s leadership, Worcester experienced unprecedented progress, with $1 billion of new economic development projects that are helping to transform an older industrial city into one that is well-positioned to lead and grow in the new economy.
As mayor, Tim chaired the Worcester School Committee and helped make that city’s schools among the best urban school systems in the nation. Tim built community partnerships to lower drop-out rates, launch school-based health initiatives and expand after-school programs to support working families.
Tim is a Worcester native and the oldest of five children. His father taught high school and his mother is a registered nurse. Tim attended Worcester public schools and went on to St. John’s High School in Shrewsbury. Tim earned his bachelor’s degree at Fordham University, and then put himself through law school attending classes at night while working days as a substitute school teacher and an advocate for homeless families. Tim earned his law degree from the Western New England College School of Law in Springfield and became a partner in the Worcester firm of Tattan, Leonard and Murray.
Tim was first elected to the Worcester City Council in 1997 and became mayor in 2001. Prior to his elective service, Tim was active for many years in a wide range of community initiatives. He served on the boards of the Worcester Public Library, Worcester Historical Museum, Worcester Community Action Council, the Worcester Working Coalition for Latino Students and Preservation Worcester.
Tim is married to Tammy (Sullivan), an occupational therapist who works with school-age children. Tim and Tammy live in Worcester with their daughters, Helen and Katerine.
James J. O'Mara
Vice President, Business Development
Ironwood Pharmaceuticals, Inc.
Jim O’Mara has served as Ironwood's vice president of business development since January 2006, and has been a leader in business development since joining the Company in October 2001. Prior to joining Ironwood, O’Mara was vice president of corporate development at Cozint Interactive, a healthcare marketing services company. He also served as a vice president for MPM Capital where he managed business development strategies and interactions for biotechnology and pharmaceutical companies. Earlier in his career, O’Mara held different sales and marketing positions at both Merck and Centocor. O’Mara earned a B.S. in pharmacy from the Massachusetts College of Pharmacy.
Office of Science and Technology
Johnson & Johnson
Cat Oyler is Sr. Director, Emerging Technologies in the Corporate Office of Science and Technology at Johnson & Johnson. Based in Boston, Massachusetts, Cat is responsible for identifying and nurturing emerging health care related technologies in the New England area, assessing technical and business risk of the new technologies, and facilitating integration of these technologies into the Johnson & Johnson Family of Companies and their product lines. In this role, Cat works with local area faculty, researchers, entrepreneurs, and investors to identify innovative product/business opportunities that will fill strategic gaps in Johnson & Johnson's current portfolio and will expand Johnson & Johnson's horizons into new "white space" therapeutic areas and businesses that are strategically aligned with the future health care environment.
Cat joins Johnson & Johnson from AstraZeneca where she was responsible for evaluating and in-licensing clinical and marketed oncology products. Additionally, Cat led the business development effort for out-licensing of AstraZeneca's oncology assets and assisted with strategic planning for oncology business development. Prior to joining AstraZeneca, Cat served in a progression of business development roles at Myriad Genetics, culminating in leading all diagnostic licensing for the Myriad Genetic Laboratories division of the company. In previous roles at Myriad, Cat worked on in- and out-licensing efforts for the pharmaceutical division, establishment of research collaborations and strategic assessment and divestment of a non-core business unit. With over ten years of BD experience and more than 15 years of biotech experience, Cat has also previously held marketing and research scientist roles at Amgen, Alza and Alkermes. Cat received a bachelor's degree in Biology from Williams College and an MBA from the UCLA Anderson School of Management.
Harry E. Figgie, Jr. Professor of Business Administration
Harvard Business School
Gary Pisano is the Harry E. Figgie, Jr. Professor of Business Administration at the Harvard Business School. Since joining the Harvard faculty in 1988, he has taught both MBA and executive level courses on technology and operations management, operations strategy, competitive strategy, product development, the management of innovation, and health care. He currently serves as chair of the Technology and Operations Management Unit.
Professor Pisano’s research has examined technology strategy, the management of product and process development, organizational learning, and vertical integration and outsourcing strategies. For the past 20 years, Pisano’s research has also focused on strategy, R&D, and competition in biotechnology and pharmaceuticals. His research has led to insights about appropriate licensing, manufacturing, and R&D strategies for biotechnology and pharmaceutical companies. Pisano is a widely published author with over 25 research papers published in such journals as Management Science, Administrative Science Quarterly, and Harvard Business Review. He has also written case studies on such companies as BMW, ITT-Automotive, Intel, Merck, Eli Lilly, and Vertex Pharmaceuticals. He is the author of The Development Factory, a book investigating the strategies and practices leading to superior development performance in biotechnology and pharmaceuticals. Pisano has also written Operations, Strategy, and Technology, with co-authors Robert Hayes, David Upton, and Steve Wheelwright. His most recent book, Science Business: The Promise, The Reality and The Future of Biotech, examines the evolution of the economic and strategic challenges facing the biotechnology sector. The book was released by HBS Press in November 2006.
Professor Pisano has served as an advisor to senior managers at such companies as Amgen, Biogen, Becton Dickinson, Eli Lilly, Johnson & Johnson, Merck, Millennium Pharmaceuticals, Novartis, Pfizer, Roche, Siegfried Pharmaceuticals, State Street Bank, and Teradyne, assisting them in creating business and operating strategies and in improving product development performance. At several of these companies, Professor Pisano has been directly involved with the management team in the implementation of these efforts. In addition, Pisano has served on the Board of Directors and Advisory Boards of a number of start-up companies.
Professor Pisano holds a Ph.D. from the University of California, Berkeley and B.A. in economics from Yale University.
Douglas J. Ringler, VMD
Cofounder, President & Chief Executive Officer
Doug is a cofounder of Tolerx, and has served as its President, Chief Executive Officer, and Director since inception in July 2000. Doug has over 25 years of experience as an academician, scientist, and executive in biomedical research focusing on the research and development of therapies designed to alter immunological responses. Doug received his BA and a VMD degree from the University of Pennsylvania. He then completed his postdoctoral training at Harvard Medical School, beginning as a Research Fellow and ultimately becoming Chairman and Associate Professor of Comparative Pathology over a 10-year time frame. Subsequently, from 1993 to 1998, Doug was a founding scientific and executive officer of LeukoSite, Inc., a biotechnology company that was ultimately sold to Millennium Pharmaceuticals in 1999, and from which two products (Campath® and Velcade®) were developed and approved for sale worldwide.
Bharat Tewarie, MD, MBA
Vice President, Head of Business Development USA
Head of Global Business Development Endocrinology/Fertility
EMD Serono Inc.
Dr. Bharat Tewarie is Vice President, Head of Business Development USA at EMD Serono, Inc. where he is responsible for business development and M&A efforts. He is also Head of Global Business Development Endocrinology/Fertility. Dr. Tewarie first joined the company in November, 1998 as Director of Marketing Planning and Development for the European region. Since then, he has held several managerial positions with increasing responsibility at the company’s global headquarters in Switzerland, including Corporate Vice President of Metabolic Endocrinology and Corporate Vice President for Reproductive Health. He served as the company’s Acting General Manager in the Netherlands before beginning his role as Executive Vice President of Reproductive Health in the United States. In this role, he was responsible for overseeing the management of sales, marketing and medical affairs for the company's infertility products.
Dr. Tewarie has an extensive background in multiple aspects of pharmaceutical management including business development, divisional P&L responsibility, sales, global marketing, clinical research and medical affairs. Prior to joining the company, he worked as an international product and medical manager in Anesthesiology and global business leader in Neurology at F. Hoffmann La Roche in Switzerland and as product manager at Boehringer Ingelheim in Germany. After his clinical practice as a medical doctor, he began his pharmaceutical career in medical affairs and clinical development at Boehringer Ingelheim in the Netherlands in 1987. Dr. Tewarie received his MD at the University of Utrecht in the Netherlands and his MBA at Webster University, also in the Netherlands.
Dr. Ted Torphy
Chief Scientific Officer and Head of External Research & Early Development (eRED)
Johnson & Johnson Pharmaceuticals
The eRED is responsible for building and managing a portfolio of external venture partner and pharmaceutical R&D collaborations on product opportunities that are of strategic interest to Johnson & Johnson. Before assuming his current role in 2007, Ted was Corporate Vice President & Head of the Corporate Office of Science & Technology, a corporate function that identifies transformational healthcare technologies for all of Johnson & Johnson's business sectors. Ted joined COSAT in 2003 after spending three years at Centocor, where he was Senior Vice President for Discovery and Preclinical Development. Prior to joining Centocor, he spent 17 years with SmithKline Beecham, most recently as Vice President of Research for the Cardiovascular, Pulmonary and Metabolic Diseases. He is the author of more than 120 journal articles, review articles, book chapters, and patents. He serves on the editorial advisory boards of eight scientific journals, chairs the Board of Directors of the Cystic Fibrosis Therapeutics, Inc., and is a board member of several other non-profit academic, research, greenhouse and venture organizations. Ted holds a B.S. degree in Pharmacy from the University of Wisconsin and a Ph.D. in Pharmacology and Toxicology from West Virginia University. He completed his postdoctoral training at the University of California, San Diego.
S. Edward Torres
Ed Torres brings over 19 years of experience in the pharmaceutical and venture capital businesses to Lilly Ventures. Since co-founding Lilly BioVentures, he has led the investments in, and previously served on the boards of, Serenex (acquired by Pfizer), Conforma Therapeutics (acquired by Biogen Idec), Cabrellis Pharmaceuticals (acquired by Pharmion Corporation) and Fluidigm. Ed currently sits on the boards of Coserics, Cylene Pharmaceuticals, Trinity Biosystems and various non-profit institutions.
Prior to his role in Lilly Ventures, Ed had a diverse set of experiences throughout the domestic and international pharmaceutical businesses including operational finance, planning, M&A, business development and global marketing roles. As a co-founder of Lilly Argentina, he was part of the management team that built a successful and profitable business there. Ed received a bachelors of arts from Creighton University and a master of business administration from the University of Michigan Business School, where he was a Consortium Fellow.
NCI Small Business Innovation Research Development Center
National Cancer Institute
Michael Weingarten is the Director for the Small Business Innovation Research (SBIR) Development Center at the National Cancer Institute, one of 27 Institutes of the National Institutes of Health (NIH) in Bethesda, Md. In this role, Mr. Weingarten manages all aspects of the NCI SBIR and Small Business Technology Transfer (STTR) programs including a portfolio of over $100M in grants and contracts annually. The SBIR and STTR programs are NCI's engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer.
In his current role, Mr. Weingarten led a team that developed a set of key recommendations for optimizing the performance of the NCI SBIR program at the NIH. Those recommendations included the establishment of an SBIR Development Center to manage the NCI SBIR program. This Center is staffed with talented leaders from both industry and the NIH who have expertise in the development and commercialization of technology in the cancer field to optimize the returns the NCI achieves through this program.
Mr. Weingarten also created and designed a brand new funding program for the NIH known as the SBIR Phase II Bridge Award, which more than triples the amount of funding available to applicants through the NCI SBIR Program. The Phase II Bridge Award will help small businesses bridge” the funding gap, known as the “Valley of Death,” that currently exists between the end of the SBIR Phase II award and the next round of financing needed to advance a promising cancer therapy or imaging technology. The new Phase II Bridge Award is specifically designed to augment previously funded NIH-wide SBIR Phase II projects in the areas of cancer therapies and cancer imaging that require additional funding in order to achieve key technical and regulatory milestones along the path toward commercialization. This new award incentivizes partnerships between NIH’s SBIR Phase II awardees and third-party investors and/or strategic partners.
Prior to joining NIH, Mr. Weingarten was the Manager of Partnership Development activities for NASA’s Technology Transfer program which included the SBIR program. In his 12 years with NASA Headquarters in Washington, D.C., Mr. Weingarten played a major role in the creation and design of NASA’s Technology Transfer program – a network of 10 NASA research centers and six regional technology transfer centers.
Mr. Weingarten has a bachelor’s degree in political science from Northwestern University, Chicago, Ill., and a master’s degree in political science from Columbia University in New York City.
Lawrence S. Wittenberg
Mr. Wittenberg, a partner in Goodwin Procter's Technology Companies Group and co-chair of its Life Sciences Practice, focuses his practice in matters involving life sciences. He joined Goodwin Procter in 2005.
Mr. Wittenberg has been an active participant in the life sciences industry since the mid-1980s, and his practice focuses exclusively on biotechnology and other life sciences companies. His clients range in size from start-ups to public companies, and he assists them with a full range of corporate and intellectual property transactions, including venture capital financings, public offerings, mergers and acquisitions, strategic alliances, joint ventures, licenses and technology transfer agreements, as well as with general legal and strategic advice.
Mr. Wittenberg also represents venture capital groups with respect to their investments in life sciences companies and investment banks in connection with public and private financings. He has structured and negotiated corporate partnering transactions with numerous world-wide pharmaceutical companies.
Prior to joining Goodwin Procter, Mr. Wittenberg was a partner in the Business Practice Group at Testa, Hurwitz & Thibeault, where he headed the Life Science Practice. Mr. Wittenberg holds a J.D. from Harvard Law School and a Bachelor's degree from Cornell University.